PREDICTORS OF G-CSF PROPHYLAXIS IN THE FIRST CYCLE OF CHEMOTHERAPY FOR FEBRILE NEUTROPENIA IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA

被引：0
|
作者：
Lugtenburg, P. [1 ]
Asubonteng, J. [2 ]
DeCosta, L. [3 ]
Szabo, Z. [4 ]
Page, J. H. [5 ]
Wetten, S. [3 ]
机构：
[1] Erasmus Mc Canc Inst, Rotterdam, Netherlands
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] Amgen Ltd, London, England
[4] Amgen Inc, Zug, Switzerland
[5] Amgen Inc, Thousand Oaks, CA USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P583
引用
收藏
页码：196 / 196
页数：1
相关论文
共 50 条
  • [31] Predictors for successful mobilization of peripheral blood progenitor cells with ESHAP plus G-CSF in patients with pretreated non-Hodgkin's lymphoma
    Liu, Jin-Hwang
    Chen, Chih-Cheng
    Bai, Li-Yen
    Chao, Shu-Chauo
    Chang, Mu-Shin
    Lin, Jeong-Shi
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2008, 71 (06) : 279 - 285
  • [32] Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with long-acting G-CSF in patients treated with chemotherapy in Germany: results of the epidemiological cross-sectional survey "G-CSF Day"
    Egerer, G.
    Uleer, C.
    Klausmann, M.
    Lueck, A.
    Schroeder, J.
    Schulz, H.
    Fichter, C.
    von der Heyde, E.
    Voss, P.
    Worth, G.
    Burbeck, M.
    Sahlmann, J.
    Potthoff, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 261 - 261
  • [33] rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin's lymphoma
    Zhu, Jun
    Hao, Si-Guo
    Hu, Jiong
    Zhuang, Jing-Li
    Wang, Chun
    Bai, Hai-Tao
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 8371 - 8377
  • [34] Intensive chemotherapy and G-CSF for HIV-associated non-Hodgkin's lymphoma (LNHIV-91 regimen)
    Oksenhendler, E
    Gerard, L
    Dubreuil, ML
    Barateau, V
    Levy, Y
    Ferchal, F
    Clauvel, JP
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 14 (04): : 103 - 103
  • [35] G-CSF IN THE MANAGEMENT OF NON-HODGKIN LYMPHOMAS
    ROSSI, JF
    PATHOLOGIE BIOLOGIE, 1993, 41 (01): : 44 - 45
  • [36] Breakthrough Febrile Neutropenia and Associated Complications in Non-Hodgkin's Lymphoma Patients Receiving Pegfilgrastim
    Ng, Jia Hui
    Ang, Xiu Yun
    Tan, Sze Huey
    Tao, Miriam
    Lim, Soon Thye
    Chan, Alexandre
    ACTA HAEMATOLOGICA, 2011, 125 (03) : 107 - 114
  • [37] G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review
    Campbell, Kim
    Chadha, Nidhi
    Dimri, Seema
    Wang, Weijia
    Li, Edward
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (07) : 619 - 633
  • [38] History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis
    Chao, C.
    Page, J. H.
    Yang, S. -J.
    Rodriguez, R.
    Huynh, J.
    Chia, V. M.
    ANNALS OF ONCOLOGY, 2014, 25 (09) : 1821 - 1829
  • [39] Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles
    van Dooijeweert, C.
    van der Wall, E.
    Baas, I. O.
    NETHERLANDS JOURNAL OF MEDICINE, 2019, 77 (09): : 310 - 316
  • [40] Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma
    Donato, ML
    Champlin, RE
    Van Besien, KW
    Korbling, M
    Cabanillas, F
    Anderlini, P
    Gajewski, JG
    Lauppe, J
    Durett, A
    Andersson, B
    Giralt, S
    Khouri, I
    Hagemeister, F
    Romaguera, JE
    Sarris, A
    McLaughlin, P
    Younes, A
    Ippoliti, C
    Blamble, DA
    Hester, J
    Gee, A
    Rodriguez, MA
    LEUKEMIA & LYMPHOMA, 1999, 35 (3-4) : 317 - 324
12345